Lb Pharmaceuticals (LBRX) Income from Continuing Operations (2024 - 2026)
Lb Pharmaceuticals' quarterly Income from Continuing Operations came in at 19054000.0 in Q1 2026, down 259.1% year-on-year from 11975897.18 in Q1 2025, and down 66.09% quarter-over-quarter from 11472000.0 in Q4 2025.
Lb Pharmaceuticals has reported Income from Continuing Operations for 3 years, with the latest figure at 19054000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 259.1% year-over-year to 19054000.0; the trailing twelve-month figure through Mar 2026 stood at 39388000.0 (changed N/A YoY), and the FY2025 full-year result was 25205000.0, up 60.06% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19054000.0, down from 11472000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3556000.0 in Q3 2025, with the low at 19054000.0 in Q1 2026.
- Average Income from Continuing Operations over 3 years is 9773333.33, with a median of 8389000.0 recorded in 2025.
- Year-over-year, Income from Continuing Operations soared 74.92% in 2025 and slumped 259.1% in 2026.
- Tracing LBRX's Income from Continuing Operations over 3 years: stood at 5071000.0 in 2024, then tumbled by 126.23% to 11472000.0 in 2025, then slumped by 66.09% to 19054000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19054000.0 (Q1 2026), 11472000.0 (Q4 2025), and 3556000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Lb Pharmaceuticals | 789.92 Mn | 789.92 Mn | - | -19.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.05 Mn |
| Dec 31, 2025 | -11.47 Mn |
| Sep 30, 2025 | -3.56 Mn |
| Mar 31, 2025 | -5.31 Mn |
| Dec 31, 2024 | -5.07 Mn |
| Sep 30, 2024 | -14.18 Mn |